News in the Life Sciences Industry

BOSTON and STOCKHOLM, Dec. 2, 2018 /PRNewswire/ -- Aprea Therapeutics presented results at the 2018 ASH Annual Meeting from its Phase Ib/II clinical study in MDS. The ongoing study is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53... Read more ››

SHANGHAI, Nov. 30, 2018 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today opened its first Bioprocess Design Center in Shanghai, China. The new center is part of a strategy to establish a center of excellence where Thermo Fisher scientists can connect and collaborate... Read more ››

BRUSSELS and ATLANTA, Nov. 30, 2018 /PRNewswire/ -- UCB is excited to be presenting 20 abstracts at this year's American Epilepsy Society Meeting, taking place between November 30 and December 4 in New Orleans, Louisiana.

BOSTON and STOCKHOLM, Nov. 30, 2018 /PRNewswire/ -- Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the closing of a EUR 50 million Series C financing round led by the Redmile Group, with... Read more ››

UPPSALA, Sweden, Nov. 30, 2018 /PRNewswire/ -- Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit has denied Actavis Elizabeth LLC's (Actavis) combined petition for panel rehearing and rehearing en banc in the case regarding Orexo's Zubsolv US patent... Read more ››

STOCKHOLM, Nov. 30, 2018 /PRNewswire/ -- According to Essity's articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated... Read more ››

LUND, Sweden, Nov. 28, 2018 /PRNewswire/ -- Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® Monthly (CAM2038) for maintenance treatment of opioid dependence within a framework of medical,... Read more ››

STOCKHOLM, Nov. 28, 2018 /PRNewswire/ -- Cancer immunotherapy - the treatment approach that utilizes and enhances the power of the immune system - looks promising. Alternative or complementary approaches are also being investigated to enhance the efficacy of the present generation of cancer immunotherapy.... Read more ››

STOCKHOLM, Nov. 28, 2018 /PRNewswire/ -- Cyxone (publ) announced today that the preclinical program for drug candidate T20K in multiple sclerosis (MS) has been concluded following positive results in the toxicology studies. The drug candidate T20K has now shown to be safe for people to ingest... Read more ››